文献速递骨质疏松与代谢性骨病

美国患者两年内停用注射类骨质疏松治疗药物的频率

Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
PubMed 文献 · Osteoporos Int · 2017-01-05

该回顾性观察研究利用行政索赔数据库,评估2008年1月至2012年6月新启动注射类骨质疏松治疗且年龄≥55岁患者的停药情况。12个月时停药概率从伊班膦酸的69.1%到地舒单抗的48.8%不等,24个月时各治疗停药率均更高。多数美国患者在启动注射类骨质疏松治疗后第一年年底前停药。

要点

  • 12个月停药率:伊班膦酸69.1%、特立帕肽67.1%、唑来膦酸59.2%、地舒单抗48.8%。
  • 24个月停药率:伊班膦酸87.5%、特立帕肽87.9%、唑来膦酸79.8%、地舒单抗64.3%。
  • 多数美国患者在启动注射类骨质疏松治疗后第一年年底前停药。

核心结论

  • 多数美国患者在启动注射类骨质疏松治疗后第一年年底前停药。

研究设计与样本

  • 回顾性观察研究,利用行政索赔数据库测量2年内每6个月间隔的注射类骨质疏松治疗停药情况。
  • 纳入年龄≥55岁、2008年1月至2012年6月间新启动注射类骨质疏松治疗、且在索引日期前≥1年及后≥1.5年连续参保的患者,随访时间18至24个月。
  • 共4756例患者符合纳入标准,其中地舒单抗617例、伊班膦酸233例、特立帕肽778例、唑来膦酸3128例。

主要发现

  • 12个月时,伊班膦酸使用者停药率最高(69.1%),其次为特立帕肽(67.1%)、唑来膦酸(59.2%)和地舒单抗(48.8%)。
  • 24个月时,各治疗停药率均更高:伊班膦酸87.5%、特立帕肽87.9%、唑来膦酸79.8%、地舒单抗64.3%。

关键数值与推荐

  • 停药定义为在各时间点未接受该时间点计划剂量的患者百分比,允许90天宽限期,敏感性分析采用60天和30天宽限期。
  • 采用Kaplan-Meier生存分析评估停药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Little is known about treatment patterns with injectable osteoporosis therapies. At 12 months, the probability of discontinuation was 69.1% among patients using ibandronate, followed by teriparatide (67.1%), zoledronic acid (59.2%), and denosumab (48.8%). By 24 months, discontinuation was higher for each treatment. The majority of US patients discontinue injectable osteoporosis treatment by the end of the first year following initiation. INTRODUCTION: This study was designed to assess the frequency of treatment discontinuation over time among patients who initiate injectable osteoporosis therapies. METHODS: This retrospective observational study utilized an administrative claims database to measure discontinuation of injectable osteoporosis therapy, reported at 6-month intervals over 2 years. Eligible patients were aged ≥55 years, had newly initiated injectable osteoporosis therapy between January 2008 and June 2012, and were continuously enrolled in the health plan for ≥1 year prior to and ≥1.5 years after the date the first injectable medication was received (the index date). Follow-up time ranged from 18 to 24 months. Injectable osteoporosis treatments included in the analysis were denosumab, ibandronate, teriparatide, and zoledronic acid. Discontinuation was assessed using Kaplan-Meier survival analysis and was defined at each time point as the percentage of patients who did not receive the dose scheduled for that time point. A 90-day grace period was allowed to accommodate flexibility in the scheduling of post-index re-administrations. Sensitivity analyses assessed discontinuation using grace periods of 60 and 30 days. RESULTS: A total of 4756 patients met the inclusion criteria for the study, with 617 utilizing denosumab, 233 ibandronate, 778 teriparatide, and 3128 zoledronic acid. At 12 months, discontinuation was highest among patients using ibandronate (69.1%), followed by teriparatide (67.1%), zoledronic acid (59.2%), and denosumab (48.8%). By 24 months, discontinuation was higher for each treatment: 87.5% for ibandronate, 87.9% for teriparatide, 79.8% for zoledronic acid, and 64.3% for denosumab. CONCLUSIONS: The majority of US patients discontinue injectable osteoporosis treatment by the end of the first year following initiation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Modi A, Sajjan S, Insinga R, et al. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int. 2017. PMID: 28058444. doi:10.1007/s00198-016-3886-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。